| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
body size and weight | Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 |
|
|
genotype assessment | Gpr84 allele assessment. PCR, sequencing. | inbred w/CC8 (58) | both | 6wks | 2013 |
|
|
ventilator
with methacholine |
Airway resistance. Baseline vs. methacholine-challenged (several doses). | inbred (37) | both | 9-12wks | 2010 |
|
|
histopathology | Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. | inbred (28) | both | 87wks | 2011 |
|
|
body weight
with influenza A (H5N1) virus |
Influenza A (H5N1) virus (several doses) vs. baseline. | inbred (23) | f | 6-9wks | 2011 |
|
|
health assessment
with influenza A (H5N1) virus |
Survival rate, influenza A (H5N1) virus (several doses). Strain H5N1 susceptibility score. | inbred (23) | f | 6-9wks | 2011 |
|
|
health assessment
with Plasmodium berghei |
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. | inbred (31) | both | 8-12wks | 2010 |
|
|
genotyping | SNP profiling, 131,000+ genomic locations, 1-19,X. | inbred (89) | 2009 | ||
|
|
genotyping | SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. | inbred (142) | m | 2014 | |
|
|
body size and weight | Body weight and length. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
complete blood count | Hematology. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
immune cell quantification | Natural killer T cells in peripheral blood, spleen, thymus. | inbred (38) | both | 8-10wks | 2011 |
|
|
behavior observation
with haloperidol |
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
body weight
with haloperidol |
Baseline vs. after haloperidol 60d implant. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
drug and metabolite quantification
with haloperidol |
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
inclined screen test
with haloperidol |
Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
open field test
with haloperidol |
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
in vitro assay
with Bacillus anthracis lethal toxin |
Bacillus anthracis lethal toxin (anthrax) susceptibility. | inbred (50) | f | 6-8wks* | 1998 |
|
|
genotype assessment
with Candida albicans |
C5 allele sufficiency or deficiency. | inbred (36) | f | 8-12wks | 2011 |
|
|
in vitro assay
with Candida albicans |
Susceptibility to infection with Candida albicans. | inbred (36) | f | 8-12wks | 2011 |
|
|
health assessment
with Plasmodium chabaudi |
Survival score and susceptibility, Plasmodium chabaudi. | inbred (25) | both | 8-10wks | 2012 |
|
|
microscopy
with Plasmodium chabaudi |
Percent of Plasmodium chabaudi-infected erythrocytes in blood. | inbred (25) | both | 8-10wks | 2012 |
|
|
body weight
with isoniazid |
Body weight. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
histopathology
with isoniazid |
Liver pathology scores. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
lipid profile
with isoniazid |
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
metabolic panel
with isoniazid |
Alanine transaminase. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
organ weights
with isoniazid |
Body, liver, kidney weights. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
biomarker quantification
with DB289 |
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
body weight
with DB289 |
DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
drug and metabolite quantification
with DB289 |
Kidney metabolite (DB75) concentration. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
metabolic panel
with DB289 |
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
organ weights
with DB289 |
Kidney and liver weights. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
urinalysis
with DB289 |
Urine volume, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
colony observation | Reproductive performance. | inbred (35) | f | various | 2009 |
|
|
ABR test | Auditory brainstem response. | inbred (51) | both | 3-12wks and 15-72wks | 2000 |
|
|
vestibular stimulus test | Vestibular function using evoked potentials. | inbred (16) | both | 49-63wks | 2003 |
|
|
urinalysis | Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. | inbred (30) | both | 52, 78, 104 wks | 2008 |
|
|
histopathology | Kidney pathology. Aging study, 6mo, 12mo, 20mo. | inbred (29) | m | 52, 78, 104 wks | 2013 |
|
|
open field test | Distance traveled, after first 10 min and after 55 min. | other (58) | both | 7-26wks | 2019 |
|
|
body weight | Body weight | inbred w/CC8 (62) | both | 8-14wks | 2021 |
|
|
open field test | Locomotor activity and grooming behavior. | inbred w/CC8 (62) | both | 8-14wks | 2021 |
|
|
body size and weight | Body length measurements. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
gait analysis | Angular velocity, Stride speed, Step length, Step width, and other gait metrics. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
open field test | Distance traveled. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
body weight | Body weight | inbred (41) | both | 8-9wks | 2010 |
|
|
running wheel monitoring | Distance, duration, speed. | inbred (41) | both | 8-9wks | 2010 |
|
|
body weight | Body weight | inbred (34) | both | 8wks | 2012 |
|
|
treadmill endurance test | Duration, distance, work. | inbred (34) | both | 8wks | 2012 |
|
|
apoptosis assessment | Aging study, 6mo, 12mo, 20mo. | inbred (30) | both | 26, 52, 87 wks | 2008 |
|
|
chromosome instability assessment | Chromosome instability. Aging study, 6mo, 12mo, 20mo. | inbred (30) | both | 26, 52, 87 wks | 2008 |
|
|
nociception assay | von Frey nociception test, baseline and after spared nerve injury (SNI) surgery as a hypersensitizer. | inbred (18) | both | 7-12wks | 2012 |
|
|
body weight
with high-fat diet and olanzapine |
Body weight and growth curve from age 8wks to 18wks weighed every 2wks. Olanzapine vs. control (both groups high-fat diet). | inbred w/CC8 (9) | f | 8-18wks | 2014 |
|
|
complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (30) | both | 26, 52, 78, 104 wks | 2007 |
|
|
complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2007 |
|
|
immune cell quantification | Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2007 |
|
|
body weight | Body weight | inbred (32) | m | 7-9wks | 2007 |
|
|
hormone quantification | Corticosterone (serum). | inbred (32) | m | 7-9wks | 2007 |
|
|
open field test | Locomotor and anxiety-related behavior. 10 min test. | inbred (32) | m | 7-9wks | 2007 |
|
|
tail suspension test | Immobility percentage. | inbred (32) | m | 7-9wks | 2007 |
|
|
proteomic profiling | Hair proteomics analysis. Spectral counts for 46 specific proteins. | inbred (11) | both | 10-19wks | 2012 |
|
|
neurotransmitter quantification | Neurotransmitters. Molecular measures. | inbred (15) | m | 7-9wks | 2003 |
|
|
open field test | Locomotor activity. 3 day trials. 45 min sessions. | inbred (15) | m | 7-9wks | 2003 |
|
|
health assessment | Post-injury wound healing. Ear cartilage and articular cartilage. | LGXSM w/par (15) | both | 6-7wks | 2012 |
|
|
histopathology | Post-injury wound healing. Articular cartilage at 12wks and 16wks post-injury. | LGXSM w/par (15) | both | 6-7wks | 2012 |
|
|
gait analysis | Aging study, 6mo, 18mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 |
|
|
grip strength | Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 |
|
|
tail cuff | Heart rate and blood pressure. Conscious mice. | inbred (25) | m | 10wks | 2007 |
|
|
study archive | Histopathology. Aging study. | inbred (28) | both | 2008 | |
|
|
body weight
with cocaine |
Body weight | inbred (45) | m | 8-11wks | 2015 |
|
|
open field test
with cocaine |
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. | inbred (45) | m | 8-11wks | 2015 |
|
|
forced swim test
with ovariectomy |
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. | inbred (37) | f | 8-10wks | 2016 |
|
|
open field test
with ovariectomy |
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. | inbred (37) | f | 8-10wks | 2016 |
|
|
genotyping | SNP profiling, 132,000+ genomic locations, 1-19,X | HMDP (248) | both | 2018 | |
|
|
mineral quantification | Liver mineral levels. Iron, copper, zinc. Iron homeostasis. | inbred (18) | both | 8wks | 2010 |
|
|
transferrin quantification | Diferric transferrin (plasma). | inbred (18) | both | 8wks | 2010 |
|
|
elevated plus maze | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 |
|
|
light-dark box | Light-dark test. Anxiety-related behavior. | inbred (38) | both | 12-14wks | 2010 |
|
|
open field test | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 |
|
|
drug and metabolite quantification
with fluoxetine |
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. | inbred (30) | m | 9-11wks | 2011 |
|
|
open field test
with fluoxetine |
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. | inbred (30) | m | 9-11wks | 2011 |
|
|
tail suspension test
with fluoxetine |
Immobility. Fluoxetine-treated vs. control. 5 min test. | inbred (30) | m | 9-11wks | 2011 |
|
|
biomarker quantification
with fluoxetine |
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. | inbred (30) | m | 10-11wks | 2011 |
|
|
ECG | Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. | inbred (29) | both | 26, 52, 87 wks | 2008 |
|
|
gait analysis | Aging study, 6mo, 12mo, 18mo. | inbred (31) | both | 26, 52, 78 wks | 2010 |
|
|
body weight | Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
hormone quantification | Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
colony observation | Life span study. Survival curves. Aging study. | inbred (31) | both | max lifespan | 2007 |
|
|
lipid profile | Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
metabolic panel | Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
colony observation | Observed age at vaginal opening (patency). Aging study. | inbred (33) | f | 2-9wks | 2009 |
|
|
tympanometry | Middle ear function. | inbred (61) | both | 15-51d | 2008 |
|
|
body weight | inbred (30) | both | 7-15 wks | 2020 | |
|
|
intake monitoring | Food and water intake; 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |
|
|
monitoring system | Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |